Pfizer Inc. recently announced convenience-based improvements made to XYNTHA® and BeneFIX®, two of the company’s recombinant factor products.
XYNTHA® is a recombinant factor VIII product indicated for the control and prevention of bleeding episodes in patients with hemophilia A (congenital factor VIII deficiency or classic hemophilia) and for surgical prophylaxis in patients with hemophilia A. BeneFIX® is a recombinant factor IX product indicated for the control and prevention of bleeding episodes in adult and pediatric patients with hemophilia B and perioperative management of adult and pediatric patients with hemophilia B.
Pfizer announced that the XYNTHA® prefilled dual-chamber syringe, the first all-in-one device for hemophilia A patients, will now be called XYNTHA® Solofuse™ syringe. Because the dual-chamber syringe contains both the freeze-dried powder and the diluent solution, it eliminates the transfer step needed for reconstitution (mixing). The device also comes with new dosing options approved by the U.S. Food and Drug Administration: 1,000 IU and 2,000 IU dosage strengths.
The company also announced that BeneFIX® may now be stored at room temperature or in the refrigerator at temperatures ranging from 36 to 86 degrees Fahrenheit (2 to 30 degrees Celsius).
Source: Pfizer Inc.
